Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 20 de 21
Filtrar
Más filtros

Banco de datos
País/Región como asunto
Tipo del documento
País de afiliación
Intervalo de año de publicación
1.
Int Ophthalmol ; 43(7): 2533-2543, 2023 Jul.
Artículo en Inglés | MEDLINE | ID: mdl-36869977

RESUMEN

PURPOSE: To investigate microcirculation characteristics of the inner retinal layers at the macula and the peripapillary area using Optical Coherence Tomography Angiography (OCT-A) of patients in early stages of Parkinson's disease (PD). METHODS: 32 PD patients and 46 age- and gender-matched healthy controls were included in this cross sectional study. OCT-A imaging was performed to analyze microcirculation characteristics at each separate macular region (fovea, parafovea, and perifovea) and the peripapillary area of the inner retinal layers. RESULTS: Individuals with PD had significantly lower parafoveal, perifoveal and total vessel density (VD) in the superficial capillary plexus (SCP) than controls (all p < 0.001), while foveal VD was higher in PD eyes than that of controls, though not statistically significant. Similarly, individuals with PD had significantly lower parafoveal, perifoveal and total perfusion in the SCP than control eyes (all p < 0.001), while foveal perfusion was significantly higher in PD eyes than that of controls (p = 0.008). PD eyes had significantly smaller FAZ area and perimeter accompanied by decreased circularity at the SCP as compared to controls (all p < 0.001). Concerning the peripapillary area, individuals with PD had significantly lower radial peripapillary capillary perfusion density and flux index at the SCP than controls (all p < 0.001). All p values remained statistically significant even after using the Bonferroni correction for multiple comparisons, except for that of foveal perfusion. CONCLUSIONS: Our study indicates alterations of the inner retinal layers at the macula and the peripapillary area at the preliminary stages of PD. OCT-A parameters could potentially comprise imaging biomarkers for PD screening and improve the diagnostic algorithms.


Asunto(s)
Enfermedad de Parkinson , Vasos Retinianos , Humanos , Estudios Transversales , Angiografía con Fluoresceína/métodos , Vasos Retinianos/diagnóstico por imagen , Enfermedad de Parkinson/diagnóstico , Microvasos , Tomografía de Coherencia Óptica/métodos
2.
J Geriatr Psychiatry Neurol ; 35(5): 680-688, 2022 09.
Artículo en Inglés | MEDLINE | ID: mdl-34663111

RESUMEN

BACKGROUND: The Parkinson's Disease-Cognitive Rating Scale (PD-CRS) is a comprehensive screening procedure for the evaluation of cognitive impairment in patients with Parkinson's disease (PD). OBJECTIVES: In the present study we adjusted the PD-CRS for the Greek population, developed normative data and examined its clinical utility for the assessment of cognitive functioning in Greek PD patients. In addition, the correlation of clinical characteristics with cognitive performance in PD patients was examined. METHODS: Three hundred four community-dwelling healthy adults and 59 patients with PD, completed the adapted PD-CRS. RESULTS: Healthy adults outperformed the PD patients on the total, the cortical and subcortical scores of the PD-CRS. Normative data indicated effects of both education and age on the PD-CRS. The optimal total PD-CRS cutoff score for the identification of cognitive impairment in a heterogeneous sample of PD patients, with regard to the severity of cognitive difficulties, was 79, yielding a modest sensitivity and specificity. Clinical characteristics of the patients (i.e., disease duration and functional disease burden) were related to poor performance on the PD-CRS. CONCLUSIONS: The Greek version of the PD-CRS is a useful instrument for the assessment of cognition in PD. Future prospective studies should examine its clinical utility to identify PD-cognitive subtypes (i.e., PD patients with mild cognitive impairment), to monitor cognitive changes, as well as its predictive accuracy for subsequent dementia.


Asunto(s)
Trastornos del Conocimiento , Disfunción Cognitiva , Enfermedad de Parkinson , Cognición , Trastornos del Conocimiento/diagnóstico , Disfunción Cognitiva/diagnóstico , Humanos , Pruebas Neuropsicológicas , Enfermedad de Parkinson/complicaciones , Enfermedad de Parkinson/diagnóstico , Estudios Prospectivos
3.
Int J Neurosci ; 130(11): 1174-1177, 2020 Nov.
Artículo en Inglés | MEDLINE | ID: mdl-32070168

RESUMEN

Purpose: To present an unusual case of posterior encephalopathy syndrome (PRES) preceded by intracranial hypotension.Materials and Methods: We present a case of a 27-year-old parturient with an uneventful pregnancy that shortly after labor developed a persistent headache with characteristics compatible with intracranial hypotension. The patient had undergone epidural anesthesia for caesarian section. Results: The symptomatology of intracranial hypotension was attributed to inadvertent dural puncture during epidural anesthesia. The MRI revealed multiple white matter lesions located in frontal, temporal and parietal regions of both hemispheres. The type of lesions was suggestive of PRES. Pachymeningeal enhancement was also observed. The patient was managed conservatively. The symptoms improved gradually and the imaging findings resolved completely. Conclusions: This case demonstrates the need for clinical alertness for PRES in patients with prolonged and possibly atypical symptoms of intracranial hypotension. As probable causal relationship between these disorders we propose a sympathetic over-activation as a result of cerebrospinal fluid leakage leading to vasospasm and manifestation of PRES.


Asunto(s)
Anestesia Epidural/efectos adversos , Hipotensión Intracraneal/etiología , Síndrome de Leucoencefalopatía Posterior/diagnóstico , Síndrome de Leucoencefalopatía Posterior/etiología , Trastornos Puerperales/etiología , Sustancia Blanca/patología , Adulto , Femenino , Humanos , Imagen por Resonancia Magnética , Sustancia Blanca/diagnóstico por imagen
4.
J Neural Transm (Vienna) ; 125(9): 1341-1349, 2018 09.
Artículo en Inglés | MEDLINE | ID: mdl-29352351

RESUMEN

We investigated whether there is a linear relationship between levodopa (LD) dose and treatment duration, and the development of levodopa-induced dyskinesia (LID) among patients with early untreated Parkinson's disease (PD). We performed a meta-analysis of randomized-controlled trials (RCTs) comparing LD monotherapy to any other antiparkinsonian treatment in early PD patients. Meta-regressions were conducted including as covariates the effects of LD dose, treatment duration, and age. We further proceeded in subgroup analyses based on the type of medications in the non-LD monotherapy (control) group and on whether patients in the control group received additional levodopa or not. Thirteen eligible RCTs were included, which revealed a significantly higher risk for dyskinesia in patients initially treated with LD monotherapy compared to any other treatment (OR = 2.82). None of the subsequent meta-regressions revealed any significant relationship with dose, treatment duration or age. Patients treated on LD monotherapy or MAOΙ plus LD were at a greater risk to develop LID than patients who received DA only or DA plus supplemental LD. The increased heterogeneity compromised the robustness of the results. The alleged correlation between LID and LD dose and treatment duration cannot be verified based on the data available so far. Well-designed, large-scale, long-term, RCTs on drug-naïve PD patients could allow the better comprehension of the pattern of the association between LID and LD treatment parameters.


Asunto(s)
Antiparkinsonianos/efectos adversos , Discinesia Inducida por Medicamentos/etiología , Levodopa/efectos adversos , Enfermedad de Parkinson/tratamiento farmacológico , Antiparkinsonianos/administración & dosificación , Antiparkinsonianos/uso terapéutico , Causalidad , Relación Dosis-Respuesta a Droga , Humanos , Levodopa/administración & dosificación , Levodopa/uso terapéutico , Enfermedad de Parkinson/fisiopatología , Ensayos Clínicos Controlados Aleatorios como Asunto , Análisis de Regresión
5.
Int J Neurosci ; 126(5): 422-8, 2016.
Artículo en Inglés | MEDLINE | ID: mdl-26000811

RESUMEN

PURPOSE OF THE STUDY: The multimodal imaging investigation of excessive daytime sleepiness (EDS) in Parkinson's disease (PD). The role of dopaminergic treatment and other clinical parameters was also evaluated. MATERIALS AND METHODS: Seventeen non-demented PD patients with EDS (PD-EDS) and 17 PD patients without EDS were enrolled. Clinical, treatment and MRI data were acquired. Gray matter (GM) volume was examined with voxel-based morphometry, while white matter (WM) integrity was assessed with diffusion tensor imaging by means of fractional anisotropy, mean diffusivity, axial diffusivity (AD) and radial diffusivity measures. RESULTS: Increased regional GM volume was found in the PD-EDS group bilaterally in the hippocampus and parahippocampal gyri. Increased AD values were also shown in the PD-EDS group, in the left anterior thalamic radiation and the corticospinal tract and bilaterally in the superior corona radiata and the superior longitudinal fasciculus. Levodopa equivalent dose differed significantly between the groups and was the only predictor of EDS, while the only predictor of the Epworth sleepiness scale score in the PD-EDS group was the dopamine-agonist dose. Increased frequency of gamblers was also observed in the PD-EDS group. CONCLUSIONS: Regional GM increases and increased AD values in certain WM tracts were found in the PD-EDS group. The changes could result from disinhibited signaling pathways or represent compensatory changes in response to anatomical or functional deficits elsewhere. The study findings support also the contribution of the total dopaminergic load in the development of EDS, while the dose of dopamine agonists was found to predict the severity of the disorder.


Asunto(s)
Encéfalo/fisiopatología , Trastornos de Somnolencia Excesiva/complicaciones , Enfermedad de Parkinson/complicaciones , Anciano , Encéfalo/patología , Imagen de Difusión Tensora , Trastornos de Somnolencia Excesiva/patología , Trastornos de Somnolencia Excesiva/fisiopatología , Femenino , Sustancia Gris/patología , Sustancia Gris/fisiopatología , Humanos , Imagen por Resonancia Magnética , Masculino , Persona de Mediana Edad , Imagen Multimodal , Enfermedad de Parkinson/patología , Enfermedad de Parkinson/fisiopatología , Sustancia Blanca/patología , Sustancia Blanca/fisiopatología
6.
Artículo en Inglés | MEDLINE | ID: mdl-38462980

RESUMEN

OBJECTIVE: The aim of the present study was to validate the Communication and Language Assessment questionnaire for persons with Multiple Sclerosis (CLAMS) into the Greek language. METHOD: 106 Persons with Multiple Sclerosis (PwMS) and 51 healthy controls (HCs) participated in this study. We evaluated patients' cognitive abilities with the Brief International Cognitive Assessment for Multiple Sclerosis (BICAMS). All PwMS completed the CLAMS and three additional questionnaires (Speech Pathology-Specific Questionnaire for persons with Multiple Sclerosis, SMS; Stroke and Aphasia Quality of Life Scale-39, SAQOL-39; the Beck Depression Inventory Fast Screen, BDI-FS), and all HCs filled in the CLAMS. RESULTS: The internal consistency of the CLAMS was excellent (a = 0.933) for the PwMS and a significant difference was found between PwMS and HCs for the total CLAMS score. Statistical analyses showed a significant positive correlation between the CLAMS and the other questionnaires (SMS, BDI, and SAQOL-39) and a statistically significant negative correlation between the CLAMS and the three subtests of the BICAMS (Symbol Digit Modalities Test, Greek Verbal Learning Test-II, and Brief Visuospatial Memory Test-Revised). There was no correlation between the CLAMS and participants' age, disease duration, and disease type. CONCLUSION: The Greek version of the CLAMS is a valid self-reported questionnaire for the evaluation of language and communication symptoms in PwMS.

7.
J Neurol Sci ; 447: 120609, 2023 04 15.
Artículo en Inglés | MEDLINE | ID: mdl-36905813

RESUMEN

Technological advancements have facilitated the availability of reliable and thorough genetic analysis in many medical fields, including neurology. In this review, we focus on the importance of selecting the appropriate genetic test to aid in the accurate identification of disease utilizing currently employed technologies for analyzing monogenic neurological disorders. Moreover, the applicability of comprehensive analysis via NGS for various genetically heterogeneous neurological disorders is reviewed, revealing its efficiency in clarifying a frequently cloudy diagnostic picture and delivering a conclusive and solid diagnosis that is essential for the proper management of the patient. The feasibility and effectiveness of medical genetics in neurology require interdisciplinary cooperation among several medical specialties and geneticists, to select and perform the most relevant test according to each patient's medical history, using the most appropriate technological tools. The prerequisites for a comprehensive genetic analysis are discussed, highlighting the utility of appropriate gene selection, variant annotation, and classification. Moreover, genetic counseling and interdisciplinary collaboration could improve diagnostic yield further. Additionally, a sub-analysis is conducted on the 1,502,769 variation records with submitted interpretations in the Clinical Variation (ClinVar) database, with a focus on neurology-related genes, to clarify the value of suitable variant categorization. Finally, we review the current applications of genetic analysis in the diagnosis and personalized management of neurological patients and the advances in the research and scientific knowledge of hereditary neurological disorders that are evolving the utility of genetic analysis towards the individualization of the treatment strategy.


Asunto(s)
Enfermedades del Sistema Nervioso , Neurología , Humanos , Medicina de Precisión , Pruebas Genéticas , Enfermedades del Sistema Nervioso/diagnóstico , Enfermedades del Sistema Nervioso/genética , Enfermedades del Sistema Nervioso/terapia , Bases de Datos Factuales , Secuenciación de Nucleótidos de Alto Rendimiento
8.
Lab Med ; 53(2): 210-214, 2022 Mar 07.
Artículo en Inglés | MEDLINE | ID: mdl-34480178

RESUMEN

The advent of next generation sequencing has revolutionized diagnostic approaches to hereditary polyneuropathies. Recently, mutations on the membrane metallo-endopeptidase (MME) gene, encoding neprilysin, have been related to the development of late-onset Charcot-Marie-Tooth disease type 2 (CMT2). Here, we report the first Greek patient presenting with a slowly progressive late-onset axonal polyneuropathy and a novel, likely pathogenic, heterozygous variant in the MME gene. In addition, we have performed a systematic review of all published case reports of patients with MME mutations. The results of the studies show that MME variants can be inherited as both fully penetrant autosomal-recessive and incompletely penetrant autosomal-dominant traits. A number of heterozygous variants characterized as incompletely penetrant impose an increased risk of developing a CMT2-like phenotype late in life, identical to the case study described here. Greater mutation numbers in different populations and mutation-specific functional studies will be essential to identify the pathogenicity and inheritance of more MME variants.


Asunto(s)
Enfermedad de Charcot-Marie-Tooth , Polineuropatías , Enfermedad de Charcot-Marie-Tooth/diagnóstico , Enfermedad de Charcot-Marie-Tooth/genética , Humanos , Mutación , Neprilisina/genética , Fenotipo , Polineuropatías/diagnóstico , Polineuropatías/genética
9.
Semin Ophthalmol ; 37(3): 399-407, 2022 Apr 03.
Artículo en Inglés | MEDLINE | ID: mdl-34612157

RESUMEN

PURPOSE: Given the fact that retina may provide a window into the central nervous system, there has been interest in identifying retinal biomarkers as predicting factors of pathological processes in neurodegenerative disorders. Emerging evidence has suggested that macular microcirculation changes in Parkinson disease (PD) may indicate the alterations of cerebral microvasculature. The use of Optical Coherence Tomography Angiography (OCT-A) has attracted significant attention in recent years as this technique offers a detailed analysis of the existence of changes at the macular capillary plexus. METHODS: A detailed review of the literature was performed in PubMed until June 2021. We identified all papers referring to the alterations of the macular capillary plexus in PD using OCT-A. RESULTS: A comprehensive update indicates that microvasculature alterations of the macular capillary plexus utilizing OCT-A may comprise useful biomarkers regarding the cerebral vasculature in PD. Since the available evidence is limited, additional studies are warranted to establish the OCT-A parameters as predicting factors in clinical practice. CONCLUSIONS: A review of the existing literature sheds light on the microvasculature changes of the macular capillary plexus as seen on OCT-A in PD patients. The current article discusses notable aspects of key publications on the topic, highlights the importance of the potential long-term effectiveness of OCT-A biomarkers in PD and proposes the need for further future research.


Asunto(s)
Enfermedad de Parkinson , Angiografía , Biomarcadores , Angiografía con Fluoresceína/métodos , Humanos , Microcirculación , Enfermedad de Parkinson/diagnóstico , Vasos Retinianos/diagnóstico por imagen , Vasos Retinianos/patología , Tomografía de Coherencia Óptica/métodos
10.
Annu Int Conf IEEE Eng Med Biol Soc ; 2021: 7617-7620, 2021 11.
Artículo en Inglés | MEDLINE | ID: mdl-34892853

RESUMEN

Palliative care for Parkinson's disease is characterized by inconsistency and varies from country to country. Although some countries have taken significant steps to include palliative care in their health programs, others, such as Greece, are still at an early stage. One step towards the widespread adoption of palliative care is the education of all stakeholders, especially clinicians. This paper presents a preliminary version of a curriculum toolkit for Palliative Care education in Parkinson's disease. Also, we explore Greek neurologists' knowledge of Palliative care based on a questionnaire and present their feedback on the topics included in this toolkit.Clinical Relevance-The toolkit aims to benefit patients in need of palliative care through promoting health literacy and further educating healthcare providers. The proposed toolkit provides all the necessary information to become sufficient knowledge and ultimately translate into clinical practice skills.


Asunto(s)
Cuidados Paliativos , Enfermedad de Parkinson , Grecia , Humanos , Neurólogos , Enfermedad de Parkinson/terapia , Encuestas y Cuestionarios
11.
Arch Clin Neuropsychol ; 36(1): 117-125, 2021 Jan 15.
Artículo en Inglés | MEDLINE | ID: mdl-32385488

RESUMEN

OBJECTIVES: The purpose of this study was to generate normative data on the Symbol Digits Modalities Test (SDMT) for the written and oral versions in the Greek adult population. We also investigated the test's validity in discriminating the performance of healthy adults from two groups of adults diagnosed with relapsing remitting (RRMS) and secondary progressive (SPMS) multiple sclerosis. METHOD: The sample consisted of 609 healthy men and women between the ages of 18 and 65. All participants were monolingual native Greek adult speakers. Each healthy participant was administered either the written (n = 460) or oral (n = 149) versions of the SDMT. Discriminant validity was examined by comparing 35 healthy participants who had completed the oral version of the SDMT to 35 age - and education-matched RRMS and SPMS patients. RESULTS: Linear regression models explained between 36% and 55% of the variance in the SDMT oral and written version scores. Age was the strongest predictor of difference in SDMT written and oral version performance, followed by education that also accounted for a further proportion of the SDMT variance. On the contrary, gender was found not to contribute significantly to the variance in the SDMT for either the written or the oral versions. As a result, age- and education-adjusted norms were generated. Regarding the tests discriminative validity, we found that both MS patient groups scored significantly lower than the healthy group. CONCLUSIONS: This is the first study to provide comprehensive normative data for the SDMT in the adult population in Greece, impacting the future practice of neuropsychological assessment in this country.


Asunto(s)
Esclerosis Múltiple , Adolescente , Adulto , Anciano , Escolaridad , Femenino , Grecia , Humanos , Modelos Lineales , Masculino , Persona de Mediana Edad , Esclerosis Múltiple/diagnóstico , Pruebas Neuropsicológicas , Adulto Joven
12.
Annu Int Conf IEEE Eng Med Biol Soc ; 2020: 532-535, 2020 07.
Artículo en Inglés | MEDLINE | ID: mdl-33018044

RESUMEN

Absence seizures are expressed with distinctive spike-and-wave complexes in the electroencephalogram (EEG), which can be used to automatically distinguish them from other types of seizures and interictal activity. Considering the chaotic nature of the EEG signal, it is very unlikely that such continuous, repetitive patterns with strict periodic behavior would occur naturally under normal conditions. Searching for spectral activity in the range of 2.5-4.5 Hz and assessing the presence of synchronous, repeated patterns across multiple EEG channels in an unsupervised manner, the proposed methodology provides high absence seizure detection sensitivity of 93.94% with a low false detection rate of 0.168 FD/h using the open TUSZ dataset.


Asunto(s)
Epilepsia Tipo Ausencia , Convulsiones , Electroencefalografía , Epilepsia Tipo Ausencia/diagnóstico , Humanos , Convulsiones/diagnóstico
13.
Brain Imaging Behav ; 13(1): 232-240, 2019 Feb.
Artículo en Inglés | MEDLINE | ID: mdl-29629498

RESUMEN

The purpose of the present study was to investigate the pattern of white matter (WM) changes associated with Parkinson's disease (PD)-related cognitive impairment by using fractional anisotropy (FA), mean diffusivity (MD), axial diffusivity (AD) and radial diffusivity (RD) measures. Diffusion Tensor Imaging (DTI) was performed in 21 PD-patients with dementia (PDD) and in an age-matched control group including 40 PD-patients without dementia (PD-CTRL). The Parkinson's disease-Cognitive Rating Scale (PD-CRS) was used for patients' neuropsychological assessment. Local microstructural WM differences associated with the presence of cognitive impairment were tested using tract-based spatial statistics analysis. Multiple regression models investigated the association of DTI indices with total PD-CRS score, PD-CRS raw items and other clinical measures across the whole study sample. Significant FA decreases were found in PDD compared to PD-CTRL patients mainly in the body of corpus callosum, corona radiata and cingulum. Lower PD-CRS score was significantly associated with decreased FA, MD and AD values in multiple WM tracts primarily located in prefrontal and limbic areas as well as across the corpus callosum. Lower performance in specific PD-CRS raw items was also associated with FA decreases in major WM tracts. The results suggest that multifocal microstructural changes of WM accompany the transition from normal to demented cognitive state in PD-patients. The corpus callosum, the corona radiata and the cingulum are among the regions mostly affected during this course. A progressive axonal degeneration is proposed as a key underlying mechanism.


Asunto(s)
Cognición , Demencia/diagnóstico por imagen , Imagen de Difusión Tensora , Enfermedad de Parkinson/diagnóstico por imagen , Enfermedad de Parkinson/psicología , Sustancia Blanca/diagnóstico por imagen , Anciano , Disfunción Cognitiva/diagnóstico por imagen , Disfunción Cognitiva/etiología , Estudios Transversales , Demencia/etiología , Imagen de Difusión Tensora/métodos , Progresión de la Enfermedad , Femenino , Humanos , Interpretación de Imagen Asistida por Computador/métodos , Masculino , Pruebas Neuropsicológicas
14.
Mov Disord ; 23(7): 950-957, 2008 May 15.
Artículo en Inglés | MEDLINE | ID: mdl-18442128

RESUMEN

The aim of the present study was to investigate the course of levodopa induced dyskinesia (LID) development in parkinsonian rats treated with several different levodopa dosing regiments. Administration of 6.25 mg/kg levodopa once daily did not induce any dyskinesia for the first 12.5 +/- 2.5 days. Then, LID gradually increased in intensity reaching an AIMs score on day 40 of 6.3 +/- 0.9. Treatment with 6.25 mg/kg of levodopa qid resulted in the rapid appearance of LID with a mean latency of 2 days and an AIMs score of 19.9 +/- 2.9 on day 10. Levodopa (25 mg/kg) once daily induced severe LID from the second day of treatment reaching an AIMs score of 35 +/- 3.2. In summary, the worst way for delivering levodopa was through intermittent administration of high doses. The daily cumulative dose of levodopa was found more important for LID induction than the total amount of levodopa received. In contrast, the best way to administer levodopa in respect to prevention/delay of LID was "low dopaminergic stimulation" with one low daily dose, instead of trying to achieve "continuous dopaminergic stimulation" using several levodopa doses throughout the day. The benefits of this strategy offered protection against severe dyskinesia even if subsequently subjects were switched to high dose levodopa.


Asunto(s)
Agonistas de Dopamina/efectos adversos , Discinesia Inducida por Medicamentos/etiología , Levodopa/efectos adversos , Enfermedad de Parkinson/tratamiento farmacológico , Animales , Ganglios Basales/patología , Agonistas de Dopamina/uso terapéutico , Relación Dosis-Respuesta a Droga , Esquema de Medicación , Levodopa/uso terapéutico , Enfermedad de Parkinson/patología , Ratas , Ratas Wistar
15.
Psychopharmacology (Berl) ; 185(3): 369-77, 2006 Apr.
Artículo en Inglés | MEDLINE | ID: mdl-16518645

RESUMEN

RATIONALE: Tardive dyskinesia is a syndrome of abnormal, involuntary movements, which occurs as a complication of long-term neuroleptic therapy. The pathophysiology of this potentially irreversible syndrome is still an enigma. OBJECTIVE: The objective of the present study was to elucidate the role of N-methyl-D-aspartate (NMDA) receptor involvement in neuroleptic-induced orofacial dyskinesia in rats. METHODS: Animals chronically treated with haloperidol for a period of 40 weeks exhibited significantly more vacuous chewing movements (VCMs), as compared to vehicle-treated controls. In a series of acute experiments, rats received: amantadine (10, 20, and 40 mg/kg i.p.), a low-affinity, uncompetitive NMDA-receptor antagonist (open channel blocker); dextrorphan (5, 10, and 20 mg/kg i.p.), an NMDA receptor channel antagonist; ifenprodil (2.5, 5, and 10 mg/kg i.p.), a noncompetitive allosteric NMDA receptor antagonist acting at the polyamine site; and Ro 25-6981 (2.5, 5, and 10 mg/kg i.p.), a potent and selective blocker of NMDA receptors which contain the NR2B subunit. RESULTS: All the drugs tested, except dextrorphan, reduced VCMs and tongue protrusions with varying efficacies and side effects profiles. Ro 25-6981 was found significantly more potent than amantadine and ifenprodil in reducing VCMs and tongue protrusions at all doses tested, and at the higher dose, it completely eliminated orofacial dyskinesia (p<0.05). CONCLUSIONS: These results suggest that NMDA receptors may play a significant role in the pathophysiology of tardive dyskinesia. Furthermore, antagonists showing selectivity for NMDA receptors containing the NR2B subunit may be particularly efficacious as novel therapeutic agents for the treatment of tardive dyskinesia and deserve further testing.


Asunto(s)
Antipsicóticos/efectos adversos , Discinesia Inducida por Medicamentos/tratamiento farmacológico , Haloperidol/efectos adversos , Receptores de N-Metil-D-Aspartato/antagonistas & inhibidores , Regulación Alostérica , Amantadina/uso terapéutico , Animales , Dextrorfano/uso terapéutico , Relación Dosis-Respuesta a Droga , Discinesia Inducida por Medicamentos/etiología , Masculino , Fenoles/uso terapéutico , Piperidinas/uso terapéutico , Ratas , Ratas Wistar
16.
Behav Brain Res ; 170(2): 337-41, 2006 Jun 30.
Artículo en Inglés | MEDLINE | ID: mdl-16621050

RESUMEN

Chronic daily administration of 6.25mg/kg of levodopa in unilaterally 6-OHDA lesioned rats did not induce any observable behavioral effects for the first 12.5+/-2.5 days. Thereafter, levodopa administration induced abnormal involuntary movements (AIMs), involving the contralateral limb, head, neck and trunk, along with the development of contralateral rotations. AIMs and rotations followed a progressively worsening, highly correlated, parallel course. We suggest that rotational behavior does not represent a pure antiparkinsonian response, but along with levodopa-induced dyskinesia is part of the levodopa-induced motor response complications syndrome.


Asunto(s)
Antiparkinsonianos/efectos adversos , Discinesia Inducida por Medicamentos/etiología , Discinesia Inducida por Medicamentos/fisiopatología , Levodopa/efectos adversos , Trastornos Parkinsonianos/tratamiento farmacológico , Rotación , Animales , Conducta Animal , Modelos Animales de Enfermedad , Masculino , Oxidopamina/toxicidad , Trastornos Parkinsonianos/inducido químicamente , Ratas , Ratas Wistar , Factores de Tiempo
17.
Annu Int Conf IEEE Eng Med Biol Soc ; 2016: 5364-5367, 2016 Aug.
Artículo en Inglés | MEDLINE | ID: mdl-28269472

RESUMEN

The ALZCARE project aims at assisting people at risk or already suffering of dementia, their family and health professionals in the dementia care pathway by providing an integrated ICT-enabled information System. The system consists of a mobile platform for screening people at risk, a Clinical Information System and a satellite-based patient tracking system. The system is currently on the evaluation phase focusing on addressing the needs of citizens of the cross-border areas of Greece and Albania.


Asunto(s)
Demencia , Sistemas de Información Geográfica , Telemedicina/métodos , Albania , Cuidadores , Sistemas de Computación , Demencia/diagnóstico , Registros Electrónicos de Salud , Grecia , Humanos , Calidad de Vida
18.
Expert Rev Neurother ; 15(2): 207-13, 2015 Feb.
Artículo en Inglés | MEDLINE | ID: mdl-25578445

RESUMEN

Dyskinesias are common, often disabling motor complications emerging in Parkinson's disease following chronic levodopa treatment. Common views associate the development of dyskinesias both with progressive loss of striatal dopamine nerve terminals and with intermittent delivery of the short half-life levodopa. Thus, according to continuous dopaminergic stimulation theory, dopamine agonists having half-lifes longer than levodopa would minimize the risk of the development of dyskinesias. The article highlights some interesting aspects of the clinical trials testing dopamine agonists monotherapy as a strategy that can reduce the risk of motor complications, and raises some concerns in terms of their early use in Parkinson's disease treatment to prevent or delay dyskinesia. Finally, we emphasize the need for reconsideration of arguments against use of levodopa as a starting therapy for Parkinson's disease.


Asunto(s)
Antiparkinsonianos/uso terapéutico , Agonistas de Dopamina/uso terapéutico , Discinesia Inducida por Medicamentos/tratamiento farmacológico , Levodopa/efectos adversos , Enfermedad de Parkinson/tratamiento farmacológico , Tiempo , Animales , Agonistas de Dopamina/administración & dosificación , Humanos , Enfermedad de Parkinson/complicaciones
19.
J Neurol Sci ; 343(1-2): 36-40, 2014 Aug 15.
Artículo en Inglés | MEDLINE | ID: mdl-24950902

RESUMEN

Parkinson's disease is a neurodegenerative disease, with a constantly increasing prevalence and a high global financial impact arising from direct and indirect costs. Large-scale, observational studies provide data that support the better comprehension of disease aspects, constitute a baseline reference for future studies and assist comparisons among different patient populations, allowing the recognition of distinctive characteristics and special needs. The present study is the first to depict the clinical characteristics and their interplay in a large sample of Parkinson's disease (PD) patients in Greece. Nine hundred eighty six consecutive PD outpatients were recruited from 17 centers around Greece in the time period from 8/2007 to 7/2009 and were examined and interviewed by movement disorders experts. Multiple clinical characteristics were recorded including age at diagnosis, disease severity, patients' self classification of PD symptoms and their relevance to physician's global clinical impression, smoking, alcohol consumption, presence of family history for PD, dementia, depression, hypertension, cancer and other comorbidities. Associations of high clinical significance were found between certain clinical characteristics.


Asunto(s)
Demencia/epidemiología , Enfermedad de Parkinson/epidemiología , Anciano , Anciano de 80 o más Años , Alcoholismo/epidemiología , Comorbilidad , Estudios Transversales , Depresión/epidemiología , Salud de la Familia , Femenino , Grecia/epidemiología , Humanos , Masculino , Programas Nacionales de Salud/estadística & datos numéricos , Prevalencia , Riesgo , Índice de Severidad de la Enfermedad , Fumar/epidemiología
20.
Eur J Pharmacol ; 683(1-3): 71-7, 2012 May 15.
Artículo en Inglés | MEDLINE | ID: mdl-22410193

RESUMEN

Long-term levodopa replacement therapy in Parkinson's disease is confounded by abnormal involuntary movements, known as levodopa induced dyskinesia (LID). Dysfunctional glutamatergic neurotransmission has been implicated in the pathogenesis of LID making metabotropic and ionotropic glutamate receptors attractive novel therapeutic targets. The objective of the present study was to investigate the antidyskinetic site of action of different glutamate receptor antagonists in the brain. For that purpose, metabotropic glutamate subtype 5 (3-((2-Methyl-1,3-thiazol-4-yl)ethynyl)pyridine hydrochloride, MTEP), NMDA NR2B selective ((aR,bS)-a-(4-Hydroxyphenyl)-b-methyl-4-(phenylmethyl)-1-piperidinepropanol maleate, Ro 25-6981) and AMPA (2,3-Dioxo-6-nitro-1,2,3,4-tetrahydrobenzo[f]quinoxaline-7-sulfonamide disodium salt, NBQX) receptor antagonists or saline were administered by intracerebral infusion in the caudate-putamen (CPu), the substantia nigra zona reticulata (SNr) or the subthalamic nucleus (STN) of 6-hydroxydopamine-lesioned rats exhibiting LID. Dyskinesia was assessed with the modified version of the rat Abnormal Involuntary Movements scale (AIMS). Ro 25-6981 and to a lesser extent NBQX improved dyskinesia (82% and 19% reduction in AIM score respectively) after infusion in the caudate-putamen. None of the three drugs managed to noticeably reduce AIM score after infusion in the SNr. MTEP was the only drug that produced a reduction in AIM score (48%) when infused in STN. In conclusion, while the striatum proved important in the antidyskinetic action of NMDA and AMPA receptor antagonists, the results of this study highlight also the importance of the metabotropic glutamate receptors that reside in the STN as therapeutic targets in the treatment of LID.


Asunto(s)
Antidiscinéticos/uso terapéutico , Modelos Animales de Enfermedad , Discinesia Inducida por Medicamentos/tratamiento farmacológico , Antagonistas de Aminoácidos Excitadores/uso terapéutico , Receptores AMPA/antagonistas & inhibidores , Receptores de Glutamato Metabotrópico/antagonistas & inhibidores , Receptores de N-Metil-D-Aspartato/antagonistas & inhibidores , Animales , Antidiscinéticos/administración & dosificación , Discinesia Inducida por Medicamentos/etiología , Discinesia Inducida por Medicamentos/fisiopatología , Antagonistas de Aminoácidos Excitadores/administración & dosificación , Infusiones Intraventriculares , Levodopa/efectos adversos , Masculino , Oxidopamina , Fenoles/administración & dosificación , Fenoles/uso terapéutico , Piperidinas/administración & dosificación , Piperidinas/uso terapéutico , Putamen/efectos de los fármacos , Quinoxalinas/administración & dosificación , Quinoxalinas/uso terapéutico , Ratas , Ratas Wistar , Receptor del Glutamato Metabotropico 5 , Sustancia Negra/efectos de los fármacos , Núcleo Subtalámico/efectos de los fármacos , Tiazoles/administración & dosificación , Tiazoles/uso terapéutico
SELECCIÓN DE REFERENCIAS
DETALLE DE LA BÚSQUEDA